A 72-year-old woman with chronic atrial fibrillation and a left ventricular ejection fraction of 35% presents with recurrent episodes of rapid ventricular response (heart rate 120–140 bpm) despite being on digoxin. Her serum potassium is 4.2 mEq/L and creatinine is 1.8 mg/dL. The cardiologist decides to add a beta-blocker rather than switching to a Class IC antiarrhythmic. Which of the following is the most important reason for avoiding a Class IC antiarrhythmic (such as flecainide) in this patient?

Explanation

## Class IC Antiarrhythmics in Heart Failure with Reduced Ejection Fraction **Key Point:** Class IC antiarrhythmics (flecainide, propafenone) are contraindicated in patients with reduced ejection fraction (HFrEF) and structural heart disease because they increase mortality through proarrhythmic mechanisms, as demonstrated by the landmark CAST trial. ### The CAST Trial and Its Legacy The Cardiac Arrhythmia Suppression Trial (CAST, 1989) fundamentally changed antiarrhythmic prescribing: - **Finding:** Flecainide and encainide (Class IC drugs) increased mortality in post-MI patients with reduced EF, despite effectively suppressing PVCs. - **Mechanism:** Proarrhythmia in the setting of structural heart disease—Class IC drugs slow conduction dramatically and can create reentrant circuits in scarred myocardium. - **Clinical implication:** Class IC drugs are now reserved for patients with structurally normal hearts (e.g., PSVT, lone AF without HF). ### Why This Patient Is High-Risk for Class IC Proarrhythmia | Risk Factor | Present in This Patient | Significance | |---|---|---| | Reduced EF (≤35%) | Yes | Structural substrate for reentry | | Age ≥70 years | Yes | Increased arrhythmia risk | | Chronic AF | Yes | Underlying electrical instability | | Renal impairment (Cr 1.8) | Yes | Potential drug accumulation | | Prior MI (implied) | Likely | Scar tissue favors reentry | **High-Yield:** The CAST trial is one of the most important studies in cardiology. Class IC drugs are **absolutely contraindicated** in: - Reduced ejection fraction (any etiology) - Prior myocardial infarction - Structural heart disease - Heart failure **Clinical Pearl:** In this patient with HFrEF and AF, the appropriate agents are: 1. **Beta-blockers** (first-line for rate control and mortality benefit) 2. **Calcium channel blockers** (if beta-blockers contraindicated) 3. **Digoxin** (already on it; useful in sedentary patients) 4. **Amiodarone** (if rhythm control needed—only Class III agent safe in HFrEF) ### Mechanism of Proarrhythmia with Class IC Drugs ```mermaid flowchart TD A[Class IC drug: flecainide]:::action --> B[Marked Na+ channel blockade]:::outcome B --> C[Slowed conduction velocity]:::outcome C --> D{Structural heart disease present?}:::decision D -->|Yes| E[Reentrant circuit formation]:::urgent D -->|No| F[Safe: used in SVT]:::action E --> G[Proarrhythmia: VT/VF]:::urgent G --> H[Increased mortality]:::urgent ``` **Mnemonic - Class IC drugs:** **FF** = Flecainide, Propafenone (both contraindicated in structural disease). Remember: "**F**lecainide is **F**orbidden in failing hearts."